fintols

Merck vs Pfizer (MRK vs PFE)

Pfizer trades at 40.1x earnings vs 139.2x for Merck; Merck grows sales faster (+4.7% vs -0.4%). Margins, debt and dividend, Nov 2026.

Quick answer

On today's data (November 19, 2026): Pfizer looks cheaper on P/E: 40.1x against 139.2x for Merck. Merck grows faster: sales +4.7% against -0.4% for Pfizer in the latest quarter. Pfizer has the better net margin: 6.3% against 3.6% for Merck.

This is a snapshot of the numbers, not a recommendation to buy or sell.

Analyze Merck freeAnalyze Pfizer free

Your first analysis is free with a free account, no card.

Short answer

On P/E as of November 19, 2026, Merck is the more expensive of the two: it trades at 139.2x its annual earnings against 40.1x for Pfizer. Merck & Co. reports two segments. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. What helps read that gap: Merck sales +4.7% against -0.4% for Pfizer in the latest quarter; net margin 3.6% against 6.3%; net debt for Merck: 1.5x EBITDA against 2.0x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.

Merck (MRK) and Pfizer (PFE) compete in healthcare and pharma. Here are Merck and Pfizer side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Merck or Pfizer.

Merck vs Pfizer: the figures

FigureMerckPfizer
Share price$137.78 (November 18, 2026)$28.06 (November 18, 2026)
Market cap$339.7 billion$159.9 billion
P/E (TTM)139.2x40.1x
Forward P/E15.4x9.5x
Revenue growth (quarter)+4.7%-0.4%
Net margin (TTM)3.6%6.3%
Net debt / EBITDA1.5x2.0x
Dividend yield2.55%6.13%
Beta0.120.30

Merck and Pfizer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Merck or Pfizer figure is not available, and we never estimate it.

3 key differences between Merck and Pfizer

  1. Valuation: Merck trades at 139.2x its annual earnings and Pfizer at 40.1x; the market pays more for each dollar of Merck profit, usually because it expects more growth.
  2. Dividend: Pfizer yields 6.13% at today's price and Merck yields 2.55%.
  3. Growth: Merck grew sales +4.7% year on year in its latest quarter, against -0.4% for Pfizer.

Merck or Pfizer: which fits your profile

Neither Merck nor Pfizer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

Verdict: Merck or Pfizer?

Of the 6 comparable figures in the table, Merck stands out on 3 (sales growth, less debt over EBITDA and lower volatility (beta)) and Pfizer stands out on 3 (net margin, lower P/E and dividend yield). That does not name a winner between Merck and Pfizer: the table is a snapshot of today, not a forecast.

You are halfway through

Keep reading free.

Create your free account to continue reading “Merck vs Pfizer (MRK vs PFE)”.

No card required

That easy

Three steps. Zero spreadsheets.

  1. 1Search a companyBy the name you know it: Apple, Inditex, Santander… ETFs too.
  2. 2Fintols does the homeworkIt reads the official filings, runs the numbers and writes the analysis for you.
  3. 3You analyze and decideWith the five answers clear, you decide. And you save the analysis to review it when the price moves.
Analyze any stock free
Analyze MRK free